logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

The Economic and Social Council advises the Government to promote investment in R&D

Source: www.actasanitaria.es

Farmaindustria has reported that the Economic and Social Council (CES), a consultative body of the Government in socio-economic and labor matters, published a comprehensive analysis of the industrial sector in Spain, in which it issues a series of recommendations for public administrations to make a determined commitment to a productive model based on R&D.

In its report ‘Industry in Spain: Proposals for its development‘, this body urges the Executive and other authorities with competences in the economic or social field to build a State Pact for Industry. “The strengthening of the industry is an indispensable condition for combining growth, employment, environmental sustainability, social cohesion and territorial structuring,” he says.

The main measures proposed by this body attached to the Ministry of Employment and Social Security and composed of 61 members of business and union organizations, as well as consumers and users and specialists in matters within the competence of the Council, revolve in relation to creating a new strategy for the R&D, which fundamentally involves “increasing public and private investment in this field to converge with the European average”.

The commitment to R&D is an essential aspect for the pharmaceutical industry to continue discovering and developing new drugs. In fact, currently, the pharmaceutical sector invests in R&D in Spain almost twice as many resources as the aeronautics and almost five times more than the computer / electronic, and it is the industrial sector that invests most in R&D (20% of total industrial business expenditure on R&D).

Investment in Spain

Specifically, according to the latest ‘Survey of R&D Activities’, of Farmaindustria, the sector invested in Spain in 2017 a total of 1,147 million euros in R&D, the historical maximum of this industry, which also represents a 5.7 percent more than the previous year.

The ESC emphasizes that industrial development must be based largely on current sectors and, therefore, considers the development of new products and businesses in those sectors “necessary”, “thereby promoting R & D & I and working on cooperation with other companies and with technology centers and universities ».

In this regard, the aforementioned report advises «fostering greater synergies between public and private R&D systems, between universities and public research centers with industrial companies», an aspect in which the pharmaceutical industry in Spain is also a pioneer .

Of the total of those 1,147 million investment in R&D, Farmaindustria points out that almost half, 47.2 percent (542.1 million), corresponded to research projects developed in collaboration with hospitals and public and private research centers (outside the walls), a chapter that grew almost 10 percent in a year and that consolidates the pharmaceutical industry in the main mobilizer of the research fabric in Spain, and especially in public research.

In Distefar we join the request that we continue to invest in the sector to continue advancing in research projects.

Related entries

19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más
14 September, 2023

Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros


Leer más
12 September, 2023

Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry


Leer más

Recent Posts

  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry
  • The rise of combination therapies in cancer opens up an opportunity for patients, but requires improved access procedures
  • The 22nd Meeting of the Spanish Pharmaceutical Industry will focus on the reform of European legislation and its impact on Spain

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.